Dr Sairah Ahmed speaks to ecancer about the three-year follow-up results from the TRANSCEND FL study.

The results demonstrate that a single infusion of lisocabtagene maraleucel (liso-cel) delivers deep, durable responses in patients with third-line or later relapsed/refractory follicular lymphoma.

Overall and complete response rates remained exceptionally high, with sustained progression-free and overall survival at 36 months, regardless of POD24 status or prior bendamustine exposure.

Dr Ahmed says that the long-term safety was favourable, with low rates of severe cytokine release syndrome, neurological events, and infections, and declining cytopenias over time.

She highlights that these findings support liso-cel as a highly effective and durable CAR T-cell therapy option for heavily pretreated follicular lymphoma.